Berlin | Japan has concluded an agreement with the alliance German-american Biontech/Pfizer to ensure that 120 million doses of their vaccine potential against the COVID-19, currently in a phase of large-scale clinical trials, announced Friday the two laboratories.
The agreement provides for “the supply of 120 million doses by the first half of 2021” conditional “regulatory approval” and “conclusive clinical trials”, specify the laboratories in a joint press release.
The price has not been specified.
The biotech German Biontech and the american laboratory Pfizer develop for several months this proposed vaccine, which came Monday in a phase of large-scale clinical trials, with 30,000 volunteers 18 to 35 years.
At the beginning of July, they had reported preliminary results positive, after having tested their vaccine on 45 people.
The objective of the two laboratories is to “produce 100 million doses before the end of the year 2020”, and “potentially more than 1.3 billion doses before the end of 2021”.
Two doses of this vaccine should be required to immunize a person, with a reminder seven days after the first injection.
While the pandemic is far from under control, governments around the world seek to ensure that stocks of vaccine in their population.
Last week, the u.s. government has entered into an agreement for 1.95 billion dollars for 100 million doses of the vaccine developed by Biontech/Pfizer.
A few days earlier the british government had also announced an agreement on the advance purchase of 30 million doses to the alliance German-american.